首页> 美国卫生研究院文献>Journal of Biomolecular Techniques : JBT >Case Study: Regulatory Considerations in the Analysis of Human Patient Samples in an Academic Core Lab
【2h】

Case Study: Regulatory Considerations in the Analysis of Human Patient Samples in an Academic Core Lab

机译:案例研究:学术核心实验室中对人类患者样本的分析中的监管注意事项

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

ANALYTICAL CHALLENGE: Absolute quantitation of propofol in 1,600 human plasma samples. REGULATORY CONSIDERATIONS: Before our core lab could accept this project, regulatory and safety aspects had to be taken into account – For clinical samples, would CLIA or GLP certification be required? Would HIPAA apply? Is propofol (infamous as the drug that killed Michael Jackson) a Controlled Substance? What about biosafety regulations? These issues will be defined and explored. In brief for this particular case study, CLIA was not required because results would not be reported back to patients or used for diagnosis. GLP was not required because data would not be used in FDA or other regulatory submissions. HIPAA did not apply because samples and data were not personally identifiable. Propofol is not classified as a controlled substance; if it were, many controlled substances can be obtained as analytical standards (in solution at low concentration) without triggering federal DEA regulations. As for biosafety, the patients were not known to have any infectious diseases, and samples were handled under “universal precautions”. SCIENTIFIC METHOD: Human plasma samples were spiked with D17-propofol (internal standard) and cleaned up via liquid-liquid extraction. The heptane extracts were analyzed without derivatization on a Scion TQ GC-triple quadrupole mass spectrometer (Bruker Daltonics) using electron ionization and SRM mode. An isocratic oven program (195C) minimized cycle time: total injection-to-injection time was 2.5 minutes. Four transitions were monitored, 2 each for propofol and D17-propofol. RESULTS: The method proved to be reliable for the analysis of 1,600 plasma samples spread over 2 months. Each 100-vial autosampler tray of samples took just over 4 hours to analyze. Calibration curves and QCs were run with each batch of samples and demonstrated consistent method performance over time. LLOQ was 4nM (400 amol on column), LLOD 2nM; response between 1nM and 4mM was linear.
机译:分析挑战:1600人血浆样品中丙泊酚的绝对定量。法规注意事项:在我们的核心实验室接受该项目之前,必须考虑法规和安全方面–对于临床样品,是否需要CLIA或GLP认证? HIPAA是否适用?异丙酚(臭名昭著的杀死迈克尔·杰克逊的药物)是受控物质吗?那么生物安全法规呢?这些问题将得到定义和探讨。简而言之,对于此特定案例研究,不需要CLIA,因为不会将结果报告给患者或用于诊断。不需要GLP,因为数据不会在FDA或其他监管文件中使用。 HIPAA不适用,因为样本和数据无法个人识别。异丙酚未归类为受控物质;如果确实如此,则可以在不触发联邦DEA法规的情况下获得许多受控物质作为分析标准品(低浓度溶液)。至于生物安全性,不知道患者有任何感染性疾病,并且样品在“普遍预防措施”下处理。科学方法:用D17-异丙酚(内标)加标人体血浆样品,并通过液-液萃取进行净化。使用电子电离和SRM模式在Scion TQ GC三重四极杆质谱仪(Bruker Daltonics)上分析庚烷提取物而不进行衍生化。等度烘箱程序(195C)最小化了循环时间:每次进样到进样的总时间为2.5分钟。监测了四个转变,丙泊酚和D17-丙泊酚各两个。结果:该方法被证明对分析2个月内分布的1600个血浆样品是可靠的。每个100瓶自动进样器样品盘仅用了4个多小时就进行了分析。每批样品均运行校准曲线和QC,并证明了随着时间的推移方法性能始终如一。 LLOQ为4nM(柱上为400 amol),LLOD为2nM; 1nM和4mM之间的反应是线性的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号